Baycol Articles
Double-digit turnover growth for Novartis
11 October 2001
Bayer looking for Euro pharma partner?
3 October 2001
Japanese pharma stocks - week to September 24
26 September 2001
Bayer health care unit not for sale but restructuring strategy revealed
17 September 2001
Analysts comment on Crestor safety data
14 September 2001
Bayer splits heath care and crop protection
13 September 2001
Stock Commentary - New York
13 September 2001
Crestor "as safe as other statins"
13 September 2001
Wenning touted to take over Bayer chairmanship
10 September 2001
Stock Commentary - Tokyo
6 September 2001
Stock Commentary - Europe
6 September 2001
Bayer faces German prosecutor's enquiry?
5 September 2001
Japan pharma stocks, week to Sept 3rd
5 September 2001
New data supports Pravachol safety
4 September 2001
ACC and AHA weigh in to support statins safety
31 August 2001
Stock Commentary - Europe
30 August 2001
Stock Commentary - New York
30 August 2001
Japan pharma stocks in week to August 27
29 August 2001
Greek deaths linked to cholesterol-lowerers
28 August 2001
Bayer takes Baycol off Japanese market
24 August 2001
GSK set to move for Bayer health unit?
20 August 2001
Bayer rejects German Ministry of Health criticism
17 August 2001
Bayer postpones NYSE listing
16 August 2001
Stock Commentary - Europe
16 August 2001
Stock Commentary - New York
16 August 2001
First actions against Bayer on Baycol
15 August 2001
Japan pharma stocks: week to August 13
14 August 2001
Stock Commentary - Europe
9 August 2001
France curbs PPA drugs, eyes cerivastatin
20 July 2001
Bayer pulls higher dose of Lipobay in UK
5 July 2001
Stroke prevention emerges from heart disease
10 January 2001
Mevalotin sales holding up at Sankyo
27 November 2000
Stock Commentary Tokyo
17 August 2000
Operating income up 31% at Bayer
10 August 2000
Bayer gains HDL-c label for Baycol
27 July 2000
Takeda benefits from strong US showing
24 May 2000
Health care boosts Bayer's Japan sales
6 April 2000
Bayer's US health care sales jump 21% in 1999
31 March 2000
Bayer looking at French acquisitions?
29 March 2000
Bayer structure to remain intact UPDATE
20 March 2000
Japan majors' price cuts will average 6%
13 March 2000
Bayer signs genomics deal with Incyte
12 January 2000
Bayer looking to Japan or the USA for a partner instead of Europe
17 November 1999
Baycol particularly effective in women
2 November 1999
Bayer health care has failed to deliver growth, say GS analysts
24 September 1999
Bayer chief executive satisfied with first-half 1999 results
12 August 1999
High-dose Baycol cleared in USA
27 May 1999
Takeda entering new phase of global expansion, says MSDW analyst
18 February 1999
Bayer Posts Flat Sales For First Nine Months Of 1998
11 November 1998
First Approval Of New Higher-Dose Cerivastatin
5 November 1998
Novartis FAME Study For Primary Prevention In Elderly
4 November 1998
Takeda Entering New Product Cycle
21 September 1998
Bayer/Fournier Market Cerivastatin In Europe
1 September 1998
Review Of US Second Qtr & Implications For Euro Firms
20 August 1998
UK Pharma Leaders Outline Strategy
22 June 1998
Bayer Looking At Strong Growth, New Products
18 June 1998
Positive Presentations At Goldman Sachs Conf
15 June 1998
Bayer "Unperturbed" By Wave Of Mergers
18 March 1998
Bayer's Cerivastatin Approved In Canada
5 March 1998
Baycol Launched In Third Major Market
19 February 1998
FDA Clears Abbott/Fournier's Tricor
13 February 1998
Abbott To Market Fournier's Fenofibrate
14 January 1998
Fournier To Copromote Baycol In Canada
13 January 1998
1997: Another Good Year For New Chemical Entities
6 January 1998
FDA Issues Talk Paper On Posicor Interactions
2 January 1998
Bayer On Track For Record Growth In 1997
13 November 1997
UK Industry Code Of Practice Report
1 September 1997
Stock Commentary Europe
31 July 1997
SB And Bayer In Baycol Deal
24 July 1997
Bayer's Baycol Cleared For US Marketing
3 July 1997
Lipobay Selected For Large UK Study In Diabetics
24 June 1997
First Launch Of Bayer's Lipobay
9 April 1997
Bayer Health Care Sales Fueled By Older Products
25 March 1997
Bayer Pharma Starts New Product Cycle
20 March 1997
Bayer's Lipobay Cleared In The UK, Its First Market
17 March 1997
Bayer's Lipobay Cleared In The UK, Its First Market
10 March 1997
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- SciClone gains China rights to Zensun's Neucardin
